Chip firm Nemesis said on Monday that it plans to commence preclincal trials for the continuous glucose monitoring (CGM) sensor in September.
The sensor will use a needle smaller than 10mm to check the glucose level of patients.
This differs from conventional blood glucose monitoring sensors that draw blood.
However, CGM has been commercialized relatively recently and is an expensive gear.
The needle used also needs to become smaller to minimize discomfort.
Nemesis said it was using enzyme-based microelectrode to reduce the size of the needle.
It also designed its own electrical and chemical bio SoC that has increased precision and life span even at low power, the company said.
This sensor will also be only a quarter of the price of the sensors currently on market, Nemesis claimed.
The company had made a prototype of the sensor that will be tried on animals in September. It will also continue to work to reduce the size of the unit, Nemesis added.
Nemesis CEO Wang Sung-ho said only those with type 1 diabetes, which accounted for 5% of the total number of diabetes patients, had access to insurance to get CGM sensor.
The company is aiming to offer its CGM sensor to those with type 2 diabetes and those vulnerable to the disease, Wang added.
The CEO, a graduate of Yonsei University and KAIST, founded Nemesis in 2017.
The company is aiming to offer various bio patches for diagnosis. Besides the CGM sensor, it is also developing vital signs monitoring solutions.